Statin use and mortality in cancer patients: Systematic review and meta-analysis of observational studies

2015 ◽  
Vol 41 (6) ◽  
pp. 554-567 ◽  
Author(s):  
Shanliang Zhong ◽  
Xiaohui Zhang ◽  
Lin Chen ◽  
Tengfei Ma ◽  
Jinhai Tang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cancer Patients ◽  
Observational Studies ◽  
Meta Analysis ◽  
Statin Use

scholarly journals The Prevalence and Predictors of Herbal Medicines’ Use in Cancer: A systematic Review and Meta-analysis of Observational Studies.

2020 ◽  
Author(s):  
John Baptist Asiimwe ◽  
Sarki Ahmed ◽  
Mauda Mugisha Kamatenesi ◽  
Esther Atukunda ◽  
Prakash PN ◽  
...  
Keyword(s):  
Systematic Review ◽  
Herbal Medicine ◽  
Cancer Patients ◽  
Observational Studies ◽  
Meta Analysis ◽  
Herbal Medicines ◽  
Medicines Use ◽  
Geographical Regions ◽  
The World ◽  
Economic Regions

The study aims to estimate the prevalence of herbal medicines use in cancer patients across the various regions of the world (geographical regions, economic regions) and establish the key predictors of herbal medicines use in those regions. The study will only synthesize literature from primary observational studies (cohorts and crosssectional study) reported in english between 2000 and 2020 (current). This study is evisaged to provide updated data on the magnitude of herbal medicine in cancer, that will in the end guide healthcare policy.

scholarly journals Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies

2021 ◽  
Vol 42 (Supplement_1) ◽  
Author(s):  
K Awad ◽  
M Mohammed ◽  
M M Zaki ◽  
A I Abushouk ◽  
G Y H Lip ◽  
...  
Keyword(s):  
Systematic Review ◽  
Primary Prevention ◽  
Older People ◽  
Lower Risk ◽  
Observational Studies ◽  
Meta Analysis ◽  
Case Control ◽  
Current Evidence ◽  
All Cause Mortality ◽  
Statin Use

Abstract Background Current evidence from randomized controlled trials on statins for primary prevention of cardiovascular disease (CVD) in older people, especially those aged >75 years, is still lacking. Purpose We conducted a systematic review and meta-analysis of observational studies to extend the current evidence about association of statin use in older people primary prevention group with risk of CVD and mortality. Methods PubMed, Scopus, and Embase were searched from inception until March 18, 2021. We included observational studies (cohort or nested case-control) that compared statin use vs non-use for primary prevention of CVD in older people aged ≥65 years; provided that each of them reported the risk estimate on at least one of the following primary outcomes: all cause-mortality, CVD death, myocardial infarction (MI), and stroke. Risk estimates of each relevant outcome were pooled as a hazard ratio (HR) with a 95% confidence interval (CI) using the random-effects meta-analysis model. Results Ten observational studies (9 cohort and one case-control study; n=872,845) fulfilled our criteria. The overall combined estimate suggested that statin therapy was associated with a significantly lower risk of all-cause mortality (HR: 0.86 [95% CI: 0.79 to 0.93]), CVD death (HR: 0.80 [95% CI: 0.78 to 0.81]), and stroke (HR: 0.85 [95% CI: 0.76 to 0.94]) and a non-significant association with risk of MI (HR: 0.74 [95% CI: 0.53 to 1.02]). The beneficial association of statins with the risk of all-cause mortality remained significant even at higher ages (>75 years old; HR: 0.88 [95% CI: 0.81 to 0.96]) and in both men (HR: 0.75 [95% CI: 0.74 to 0.76]) and women (HR: 0.85 [95% CI: 0.72 to 0.99]). However, this association with the risk of all-cause mortality remained significant only in those with DM (HR: 0.82 [95% CI: 0.68 to 0.98]) but not in those without DM. Conclusions Statin therapy in older people (aged ≥65 years) without CVD was associated with a 14%, 20% and 15% lower risk of all-cause mortality, CVD death and stroke, respectively. The beneficial association with the risk of all-cause mortality remained significant even at higher ages (>75 years old), in both men and women, and in individuals with DM, but not in those without DM. These observational findings support the need for trials to test benefits of statins in those above 75 years of age. FUNDunding Acknowledgement Type of funding sources: None. Figure 1. Results of the meta-analysis

scholarly journals Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies

BMC Medicine ◽  
2021 ◽  
Vol 19 (1) ◽  
Author(s):  
Kamal Awad ◽  
Maged Mohammed ◽  
Mahmoud Mohamed Zaki ◽  
Abdelrahman I. Abushouk ◽  
Gregory Y. H. Lip ◽  
...  
Keyword(s):  
Systematic Review ◽  
Primary Prevention ◽  
Older People ◽  
Lower Risk ◽  
Observational Studies ◽  
Meta Analysis ◽  
Case Control ◽  
Current Evidence ◽  
All Cause Mortality ◽  
Statin Use

Abstract Background Current evidence from randomized controlled trials on statins for primary prevention of cardiovascular disease (CVD) in older people, especially those aged > 75 years, is still lacking. We conducted a systematic review and meta-analysis of observational studies to extend the current evidence about the association of statin use in older people primary prevention group with risk of CVD and mortality. Methods PubMed, Scopus, and Embase were searched from inception until March 18, 2021. We included observational studies (cohort or nested case-control) that compared statin use vs non-use for primary prevention of CVD in older people aged ≥ 65 years; provided that each of them reported the risk estimate on at least one of the following primary outcomes: all cause-mortality, CVD death, myocardial infarction (MI), and stroke. Risk estimates of each relevant outcome were pooled as a hazard ratio (HR) with a 95% confidence interval (CI) using the random-effects meta-analysis model. The quality of the evidence was rated using the GRADE approach. Results Ten observational studies (9 cohorts and one case-control study; n = 815,667) fulfilled our criteria. The overall combined estimate suggested that statin therapy was associated with a significantly lower risk of all-cause mortality (HR: 0.86 [95% CI 0.79 to 0.93]), CVD death (HR: 0.80 [95% CI 0.78 to 0.81]), and stroke (HR: 0.85 [95% CI 0.76 to 0.94]) and a non-significant association with risk of MI (HR 0.74 [95% CI 0.53 to 1.02]). The beneficial association of statins with the risk of all-cause mortality remained significant even at higher ages (> 75 years old; HR 0.88 [95% CI 0.81 to 0.96]) and in both men (HR: 0.75 [95% CI: 0.74 to 0.76]) and women (HR 0.85 [95% CI 0.72 to 0.99]). However, this association with the risk of all-cause mortality remained significant only in those with diabetes mellitus (DM) (HR 0.82 [95% CI 0.68 to 0.98]) but not in those without DM. The level of evidence of all the primary outcomes was rated as “very low.” Conclusions Statin therapy in older people (aged ≥ 65 years) without CVD was associated with a 14%, 20%, and 15% lower risk of all-cause mortality, CVD death, and stroke, respectively. The beneficial association with the risk of all-cause mortality remained significant even at higher ages (> 75 years old), in both men and women, and in individuals with DM, but not in those without DM. These observational findings support the need for trials to test the benefits of statins in those above 75 years of age.

Sign in / Sign up

Export Citation Format

Share Document